2021
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit
Mazloomzadeh S, Khaleghparast S, Ghadrdoost B, Mousavizadeh M, Baay M, Noohi F, Sharifnia H, Ahmadi A, Tavan S, Malekpour Alamdari N, Fathi M, Soleimanzadeh M, Mostafa M, Davoody N, Zarinsadaf M, Tayyebi S, Farrokhzadeh F, Nezamabadi F, Soomari E, Sadeghipour P, Talasaz A, Rashidi F, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M, Sezavar S, Payandemehr P, Dabbagh A, Moghadam K, Jamalkhani S, Khalili H, Yadollahzadeh M, Riahi T, Rezaeifar P, Tahamtan O, Matin S, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abri H, Tabrizi S, Mousavian S, Shahmirzaei S, Bakhshandeh H, Amin A, Rafiee F, Baghizadeh E, Mohebbi B, Parhizgar S, Aliannejad R, Eslami V, Kashefizadeh A, Kakavand H, Hosseini S, Shafaghi S, Ghazi S, Najafi A, Jimenez D, Gupta A, Madhavan M, Sethi S, Parikh S, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane A, Van Tassell B, Dobesh P, Stone G, Lip G, Krumholz H, Goldhaber S, Bikdeli B. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA 2021, 325: 1620-1630. PMID: 33734299, PMCID: PMC7974835, DOI: 10.1001/jama.2021.4152.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsCOVID-19Drug Administration ScheduleEnoxaparinExtracorporeal Membrane OxygenationFemaleHemorrhageHospitalizationHumansIntensive Care UnitsIranLength of StayMaleMiddle AgedOdds RatioOutcome Assessment, Health CareOxygen Inhalation TherapyPulmonary EmbolismThrombocytopeniaThrombosisTreatment OutcomeVenous ThrombosisConceptsStandard-dose prophylactic anticoagulationIntensive care unitIntermediate-dose groupProphylactic anticoagulationPrimary efficacy outcomeExtracorporeal membrane oxygenationIntermediate doseMajor bleedingProphylaxis groupEfficacy outcomesMembrane oxygenationPrimary outcomeThrombotic eventsArterial thrombosisCare unitSevere thrombocytopeniaCOVID-19Bleeding Academic Research ConsortiumExtracorporeal membrane oxygenation treatmentPrespecified safety outcomesRoutine empirical useStandard prophylactic anticoagulationAcademic Research ConsortiumMembrane oxygenation treatmentAntithrombotic prophylaxis
2015
National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient‐Centered Evaluative Assessment of Cardiac Events (PEACE)–Retrospective AMI Study
Zhang L, Desai NR, Li J, Hu S, Wang Q, Li X, Masoudi FA, Spertus JA, Nuti SV, Wang S, Krumholz HM, Jiang L, Group T. National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient‐Centered Evaluative Assessment of Cardiac Events (PEACE)–Retrospective AMI Study. Journal Of The American Heart Association 2015, 4: e001906. PMID: 26163041, PMCID: PMC4608074, DOI: 10.1161/jaha.115.001906.Peer-Reviewed Original ResearchMeSH KeywordsAgedAsian PeopleChinaClopidogrelDrug Administration ScheduleFemaleHealthcare DisparitiesHumansMaleMiddle AgedMyocardial InfarctionNational Health ProgramsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Quality ImprovementQuality Indicators, Health CareResidence CharacteristicsRetrospective StudiesRisk FactorsRural Health ServicesTiclopidineTime FactorsTreatment OutcomeUrban Health ServicesConceptsAcute myocardial infarctionEarly clopidogrel useClopidogrel therapyClopidogrel useRural hospitalsMyocardial infarctionQuality improvement initiativesEligible patientsClopidogrel administrationReperfusion therapyCardiac eventsHospital admissionAMI patientsChina PatientChinese patientsPatterns of useUrban hospitalPatientsClopidogrelChinese trialsHospitalTherapyEarly useAMI studyImprovement initiatives
2014
Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001–2011: The China PEACE‐Retrospective AMI Study
Gao Y, Masoudi FA, Hu S, Li J, Zhang H, Li X, Desai NR, Krumholz HM, Jiang L, Group T. Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001–2011: The China PEACE‐Retrospective AMI Study. Journal Of The American Heart Association 2014, 3: e001250. PMID: 25304853, PMCID: PMC4323779, DOI: 10.1161/jaha.114.001250.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAspirinChinaCohort StudiesConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleFemaleHospital MortalityHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionOdds RatioRetrospective StudiesRisk AssessmentRural PopulationSecondary PreventionSex FactorsSurvival AnalysisSurvival RateUrban PopulationConceptsAcute myocardial infarctionMyocardial infarctionAspirin useEarly treatmentSegment elevation acute myocardial infarctionElevation acute myocardial infarctionEarly useChina PEACE-Retrospective AMI StudyEarly aspirin therapyEarly aspirin useLimited healthcare resourcesAspirin therapyCardiogenic shockChest discomfortReperfusion therapyRate of useChina PatientRetrospective studyPatient groupFinal diagnosisHealthcare resourcesInfarctionPatientsAspirinAMI study
2010
Persistence of Cardiovascular Risk After Rofecoxib Discontinuation
Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM. Persistence of Cardiovascular Risk After Rofecoxib Discontinuation. JAMA Internal Medicine 2010, 170: 2035-2036. PMID: 21149763, PMCID: PMC3024905, DOI: 10.1001/archinternmed.2010.461.Peer-Reviewed Original ResearchOptimizing statin treatment for primary prevention of coronary artery disease.
Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Annals Of Internal Medicine 2010, 152: 69-77. PMID: 20083825, DOI: 10.7326/0003-4819-152-2-201001190-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCholesterol, LDLClinical Trials as TopicComputer SimulationCoronary Artery DiseaseDrug Administration ScheduleFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrimary PreventionQuality-Adjusted Life YearsRisk FactorsSensitivity and SpecificityTreatment OutcomeConceptsHigh-dose statinsQuality Enhancement Research InitiativeStatin therapyMore QALYsNational Cholesterol Education Program III guidelinesTreatment approachesCoronary artery disease preventionVeterans Affairs Health Services ResearchDoses of statinsCoronary artery diseaseRisk factor dataAvailable clinical dataYears of treatmentTarget approachBase-case analysisHealth services researchPersons 75 yearsStatin doseStatin trialsCAD eventsStatin treatmentArtery diseaseCAD riskPrimary preventionMyocardial infarction
2009
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)
Kushner FG, Hand M, Smith SC, King SB, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE, Green LA, Jacobs AK, Hochman JS, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Catheterization And Cardiovascular Interventions 2009, 74: e25-e68. PMID: 19924773, DOI: 10.1002/ccd.22351.Peer-Reviewed Original Research
2006
Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement
Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement. Circulation 2006, 113: 2803-2809. PMID: 16769908, DOI: 10.1161/circulationaha.106.618066.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryCardiovascular AgentsCause of DeathClopidogrelCombined Modality TherapyCoronary RestenosisDrug Administration ScheduleDrug ImplantsFemaleFollow-Up StudiesHospitalizationHumansLife TablesMaleMiddle AgedMortalityMyocardial InfarctionPatient Education as TopicPlatelet Aggregation InhibitorsPrevalenceProportional Hazards ModelsProspective StudiesPyridinesRegistriesSirolimusStentsSurvival AnalysisThrombosisTiclopidineTreatment OutcomeTreatment RefusalConceptsDrug-eluting stentsThienopyridine therapyMI patientsMyocardial infarctionCardiac rehabilitation referralUse of thienopyridinesAcute myocardial infarctionPremature discontinuationDES placementRehabilitation referralHospitalization ratesStent thrombosisDischarge instructionsStent placementCardiovascular diseaseSubsequent mortalityPatientsDES treatmentTherapyHealth careMonthsThienopyridinesMortalityPrevalenceDays
2004
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB, Investigators A. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). The American Journal Of Cardiology 2004, 94: 279-283. PMID: 15276088, DOI: 10.1016/j.amjcard.2004.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPartial Thromboplastin TimeProbabilityRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival RateTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsWeight-adjusted heparinST-elevation myocardial infarctionASSENT-3Myocardial infarctionASSENT-2Major bleedingIntracranial hemorrhageSmall doseFull-dose tenecteplaseLess major bleedingNew thrombolytic regimenOutcomes of patientsAcute myocardial infarctionPartial thromboplastin timeSimilar ratesRefractory ischemiaThrombolytic regimenRecurrent infarctionBaseline characteristicsHemorrhagic complicationsUnfractionated heparinThromboplastin timePatientsInfarctionTenecteplase